Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LPX EWS/FL1 T1

Next Previous
Drug Profile

LPX EWS/FL1 T1

Alternative Names: Bi-shRNAEWS-FLI-Type-1-LPX; pbi-functional short hairpin RNA EWS/FLI2 type 1 lipoplex; pbi-functional shRNA EWS-FLI2 type 1 lipoplex; pbi-shRNA™ EWS/FLI1 Type 1 LPX

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gradalis
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ewing's sarcoma

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Ewing's Sarcoma(In adolescents, In children, Late-stage disease, Second-line therapy or greater, In adults) in USA (IV, Infusion)
  • 26 Jul 2023 Phase I development is ongoing in Ewing's Sarcoma (In adolescents, In children, Late-stage disease, Second-line therapy or greater, In adults) in USA (IV, Infusion) (NCT02736565)
  • 01 Mar 2023 Gradalis completes a phase I trial in Ewing's Sarcoma (Late-stage disease, Second-line therapy or greater, In children, In adolescents, In adults) in USA (IV) (NCT02736565)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top